Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
108.85
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
March 23, 2022
- Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day
March 22, 2022
mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV) mRNA-1287 is a vaccine candidate against the four endemic human...
From
ModernaTX, Inc
Via
AccessWire
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
March 21, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
March 17, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
March 17, 2022
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
March 16, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
March 14, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
March 10, 2022
Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273) Moderna expects...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
March 10, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces Its Global Public Health Strategy
March 07, 2022
Moderna announces commitment to advance vaccines targeting 15 pathogens identified as biggest public health risk by WHO and CEPI into clinical studies by 2025 Moderna launches mRNA Access, a new...
From
Moderna, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
March 07, 2022
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities Moderna investing up to $500 million to produce up to 500 million doses each year for the African...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
March 03, 2022
The Americas Enterprise Solutions Hub will support the U.S., Canada and Latin America and is in addition to Moderna's International Enterprise Solutions Hub in Warsaw, Poland Atlanta selected due to...
From
Moderna, Inc.
Via
AccessWire
Moderna to Present at Upcoming Conferences in March 2022
March 02, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 2, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the...
From
Moderna, Inc.
Via
AccessWire
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
February 24, 2022
Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older....
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
February 24, 2022
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29 Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of...
From
Moderna, Inc.
Via
AccessWire
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
February 23, 2022
From
Thermo Fisher Scientific Inc. and Moderna, Inc.
Via
Business Wire
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
February 22, 2022
Moderna has a commercial footprint in 56 countries across the world through direct presence and distributors and plans expansion in ten additional markets in 2022 Moderna also supplies the Company's...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
February 22, 2022
Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in...
From
Moderna, Inc.
Via
AccessWire
Moderna Expands Its mRNA Pipeline with Three New Development Programs
February 18, 2022
mRNA-1608 is a vaccine candidate against Herpes simplex virus (HSV) mRNA-1468 is a vaccine candidate against varicella-zoster virus (VZV) to reduce the rate of herpes zoster (shingles) mRNA-4359 is a...
From
Moderna, Inc.
Via
AccessWire
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)
February 16, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 16, 2022 / Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries
February 16, 2022
Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region Local commercial...
From
Moderna, Inc.
Via
AccessWire
Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
February 16, 2022
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID,...
From
Moderna, Inc.
Via
AccessWire
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
February 16, 2022
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years....
Via
FinancialNewsMedia
Exposures
COVID-19
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
February 15, 2022
Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local...
From
Moderna, Inc.
Via
AccessWire
Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering
February 09, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Chief...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine
February 08, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
February 03, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 3, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live...
From
Moderna, Inc.
Via
AccessWire
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
January 31, 2022
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
January 27, 2022
Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and...
From
Moderna, Inc.
Via
AccessWire
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
January 26, 2022
Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including...
From
Moderna, Inc.
Via
AccessWire
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.